Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lanreotide (Somatuline) vs Pasireotide (Signifor)
An educational, source-based comparison of Lanreotide (Somatuline) and Pasireotide (Signifor) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting somatostatin analog for acromegaly and NETs.
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.
- Acromegaly
- Gastroenteropancreatic NETs
- Carcinoid syndrome
- • FDA-approved.
- • Monitor gallbladder, glucose, and thyroid function.
Multi-receptor somatostatin analog for Cushing's disease and acromegaly.
Cyclohexapeptide somatostatin analog binding somatostatin receptors SST1, 2, 3, and 5 (with highest affinity for SST5), suppressing ACTH in corticotroph adenomas and GH/IGF-1 in somatotroph tumors.
- Cushing's disease
- Acromegaly (LAR formulation)
- • FDA-approved.
- • Significant hyperglycemia risk requires glucose monitoring.
- • Bradycardia and QT prolongation possible.
Lanreotide (Somatuline) vs Pasireotide (Signifor) — Key differences
- Class: Lanreotide (Somatuline) is classified as Somatostatin Analog · Oncology, while Pasireotide (Signifor) is Somatostatin Analog · Endocrine.
- Primary research focus: Lanreotide (Somatuline) — acromegaly; Pasireotide (Signifor) — cushing's disease.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.